An appetite change is not a reliable test of AOD-9604 activity or benefit. Appetite, energy expenditure, fat metabolism and weight are related but distinct outcomes, and evidence for one should not be substituted for another.
Begin with the research setting
The AOD9604 mouse experiments investigated metabolic effects in animal models. They do not establish an appetite-suppression treatment in people or predict what a person should feel after exposure.
The FDA's clinical review considers the human obesity program and its limitations. A metabolic rationale did not translate into the hoped-for result in the large oral study.
Describing a substance as fat burning therefore does not answer whether it changes appetite, improves health or produces a clinically meaningful result.
Multiple exposures make attribution difficult
If a person is also taking a weight-management medicine, a change in appetite cannot automatically be assigned to AOD-9604. The timing of other care, illness, diet and expectations may matter.
Likewise, no appetite change does not establish that a vial is inactive. It may simply be an outcome for which the proposed expectation was not validated.
Strong sensations are not a product-quality test. They cannot establish identity, amount or a favorable risk-benefit balance.
Use outcomes that match the question
A claim about appetite requires a suitable appetite measure and a relevant comparison. A claim about body fat requires an appropriate body-composition measure. A claim about treatment benefit also requires harms and clinical context.
A personal observation can be brought to a clinician, but it should remain an observation rather than a laboratory assay or proof of mechanism.
The evidence cited here does not establish a reliable appetite-based way to judge AOD-9604 or decide whether to increase exposure. If an established treatment is producing unwanted hunger changes or disappointing results, review that treatment with its prescriber rather than using an experimental add-on to test a theory.